I-Mab Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Sean Fu

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	5.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Sean Fu

less than a year

Permanencia

Dr. Xi-Yong Fu, also known as Sean, PhD, MBA, is Director & Interim CEO of I-Mab from July 15, 2024. Along with being Director of I-Mab, Dr. Fu is also an Operating Partner of ABio-X. Before joining ABio-X...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Xi-Yong Fu	Director & Interim CEO	less than a year	sin datos	sin datos
Skelton Joseph	Chief Financial Officer	less than a year	sin datos	sin datos
Tianyi Zhang	Vice President of Investor Relations	no data	sin datos	sin datos
Fernando J. Salle´s	Senior VP and Head of U.S. & EU Business Development	4.6yrs	sin datos	sin datos
Louie Naumovski	Interim Chief Medical Officer	less than a year	sin datos	sin datos
Phillip Dennis	Chief Medical Officer	less than a year	sin datos	sin datos
Tyler Ehler	Senior Director of Investor Relations	no data	sin datos	sin datos

0.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 0VY no se considera experimentado ( 0.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Xi-Yong Fu	Director & Interim CEO	less than a year	sin datos	sin datos
Eric Rowinsky	Member of Scientific Advisory Board	5.3yrs	sin datos	sin datos
Roy Steven Herbst	Member of Scientific Advisory Board	5.3yrs	sin datos	sin datos
Howard L. Weiner	Member of Scientific Advisory Board	5.3yrs	sin datos	sin datos
Chia-Hung Yang	Independent Director	4.8yrs	sin datos	sin datos
Chun Kwok Au	Independent Director	4.8yrs	sin datos	sin datos
Fu Wei	Chairman	6.3yrs	sin datos	sin datos
Timothy A. Yap	Member of Scientific Advisory Board	5.2yrs	sin datos	sin datos
Patricia LoRusso	Member of Scientific Advisory Board	5.3yrs	sin datos	sin datos
Jun Ma	Member of Scientific Advisory Board	3.8yrs	sin datos	sin datos
Lielie Zhang	Independent Director	less than a year	sin datos	sin datos

5.2yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de 0VY se considera experimentada (5 años de antigüedad promedio).

I-Mab Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-Mab Announces Board Changes , Effective February 10, 2024

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

Less than half of directors are independent

Recent updates

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

First half 2024 earnings released: US$0.19 loss per share (vs US$1.32 loss in 1H 2023)

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Market cap size

Insufficient new directors

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings released: CN¥16.53 loss per share (vs CN¥29.23 loss in FY 2022)

New minor risk - Financial data availability

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New major risk - Share price stability

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

First half 2022 earnings released: CN¥12.75 loss per share (vs CN¥14.67 loss in 1H 2021)

Less than half of directors are independent

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma At ASH 2021

I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

Investor sentiment deteriorated over the past week

I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of Its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe Covid-19

Investor sentiment deteriorated over the past week

I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio

I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥8.07 (vs CN¥463 loss in FY 2019)

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥8.07 (vs CN¥463 loss in FY 2019)

I-Mab to Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab At 2021 American Association for Cancer Research Annual Meeting

I-Mab to Report Fiscal Year 2020 Results on Mar 29, 2021

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors

I-Mab has completed a Follow-on Equity Offering in the amount of $177.3333 million.

I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73 Antibody Uliledlimab in China and the U.S

I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China

New 90-day high: €51.00

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

New 90-day high: €37.60

Revenue in line with expectations

I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China

Revenue in line with expectations

I-Mab Announces Appointments to its Scientific Advisory Board